But the new drug, prasugrel (Effient), is also more likely to cause potentially fatal bleeding. Overall, prasugrel may be superior to the approved dose of the older drug, clopidogrel (Plavix), in ...

Prasugrel is used with aspirin by patients ... blood clots after certain procedures (such as cardiac stent). This medication is used to prevent strokes in people who cannot take aspirin or for ...

This medication is a platelet aggregation inhibitor, prescribed for thrombotic cardiovascular (CV) events (life-threatening problems with the heart and blood vessels), in patients who had heart ...

(See "Lilly's Prasugrel Pleases FDA Panel.") But halfway through the panel discussion, the committee members seem relatively unconcerned by the cancer risk and it seems more likely that the drug ...

Prasugrel is a platelet aggregation inhibitor, prescribed for thrombotic cardiovascular (CV) events (life-threatening problems with the heart and blood vessels), in patients who had heart disease ...

A loading dose of study medication (60 mg of prasugrel or 300 mg of clopidogrel) was administered, in a double-blind manner, anytime between randomization and 1 hour after leaving the cardiac ...

This potentially dangerous drug-drug interaction is at least partly alleviated by administering prasugrel at the end of the cangrelor infusion, the currently recommended approach for switching between ...

In order to better prevent blood clots, the drugs clopidogrel or prasugrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid (ASA).

WASHINGTON A new drug, prasugrel, manufactured by Eli Lilly and Daiichi Sankyo, has been granted a priority review by the Food and Drug Administration. The drug is intended for the prevention of ...

A panel of outside advisers is meeting today to give guidance to the FDA on how to handle prasugrel, the anticlotting drug that Eli Lilly hopes will be its next blockbuster. With safety so central ...

After adjustment to the final maintenance dose of the study drug or placebo, platelet reactivity was lower in the prasugrel group than in the placebo group (mean difference, −72.4 PRUs ...